. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh: See more » Antineoplastic Agents/therapeutic useDrug ApprovalHumansIndoles/adverse effectsIndoles/therapeutic useMelanoma/drug therapyMelanoma/pathologyMutationNeoplasm MetastasisProto-Oncogene Proteins B-raf/antagonists & inhibitorsProto-Oncogene Proteins B-raf/geneticsSulfonamides/adverse effectsSulfonamides/therapeutic useUnited StatesUnited States Food and Drug AdministrationVemurafenib
Substances: See more » Antineoplastic AgentsIndolesSulfonamidesVemurafenibProto-Oncogene Proteins B-raf
Year: 2011 PMID: 22010387
Source DB: PubMed Journal: Oncology (Williston Park) ISSN: 0890-9091 Impact factor: 2.990